X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-27 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $13.79 | +2,000 | 31,007 | +7% | +$27,580 | ||||||
2026-08-26 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale | $1.56 | -2,000 | 127,777 | -2% | -$3,116 | ||||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
2026-08-28 | BIVI | Biovie Inc. | Palumbo Joseph M | Chief Medical Officer | P - Purchase | $2.16 | +4,843 | 6,036 | +406% | +$10,461 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Chappell Amy Suzon | Dir | P - Purchase | $2.16 | +727 | 727 | New | +$1,570 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Kim Joanne Wendy | CFO | P - Purchase | $2.18 | +2,500 | 3,441 | +266% | +$5,450 | ||||||
2026-08-27 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $2.08 | +15,210 | 16,117 | >999% | +$31,637 | ||||||
2026-08-26 | PGEN | Precigen, Inc. | Kindler Jeffrey B | Dir | S - Sale | $7.44 | -185,000 | 17,100 | -92% | -$1,376,400 | ||||||
| AD | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $111.39 | -4,090 | 11,486 | -26% | -$455,567 | |||||
| AD | 2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale+OE | $111.98 | -3,142 | 5,373 | -37% | -$351,835 | |||||
| D | 2026-08-27 | ARQT | Arcutis Biotherapeutics, Inc. | Curran Terrie | Dir | S - Sale+OE | $25.03 | -38,200 | 23,526 | -62% | -$956,123 | |||||
| M | 2026-08-26 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $72.26 | -25,000 | 1,499,860 | -2% | -$1,806,509 | |||||
| D | 2026-08-28 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | S - Sale+OE | $59.07 | -50,000 | 59,745 | -46% | -$2,953,572 | |||||
| DM | 2026-08-26 | OMER | Omeros Corp | Hanish Arnold C | Dir | S - Sale+OE | $18.81 | -15,000 | 12,400 | -55% | -$282,094 | |||||
| D | 2026-08-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.57 | -9,500 | 668,728 | -1% | -$4,964,376 | |||||
2026-08-26 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.96 | -300 | 141,002 | 0% | -$4,188 | ||||||
| D | 2026-08-26 | CORT | Corcept Therapeutics Inc | Park Kimberly | Dir | S - Sale+OE | $122.55 | -26,685 | 0 | -100% | -$3,270,169 | |||||
2026-08-26 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | S - Sale | $2.97 | -18,300 | 2,840,635 | -1% | -$54,351 | ||||||
| D | 2026-08-26 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.69 | -77,000 | 69,828 | -52% | -$1,053,814 | |||||
| D | 2026-08-26 | MNPR | Monopar Therapeutics | Rioux Patrice | Acting Chief Medical Officer | S - Sale+OE | $111.26 | -1 | 5,065 | 0% | -$111 | |||||
2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale | $111.39 | -4,090 | 7,396 | -36% | -$455,567 | ||||||
2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale | $111.77 | -3,142 | 23,751 | -12% | -$351,189 | ||||||
2026-08-25 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $380.00 | -280 | 1,286,449 | 0% | -$106,400 | ||||||
| D | 2026-08-25 | ABT | Abbott Laboratories | Ford Robert B | COB, CEO | S - Sale+OE | $115.85 | -398,832 | 522,664 | -43% | -$46,204,798 | |||||
| D | 2026-08-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.28 | -9,500 | 668,728 | -1% | -$4,914,190 | |||||
2026-08-26 | CYPH | Cypherpunk Technologies Inc. | Dietz Thomas John | Dir | S - Sale | $1.72 | -20,000 | 132,500 | -13% | -$34,400 | ||||||
| D | 2026-08-25 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $125.58 | -30,955 | 119,472 | -21% | -$3,887,320 | |||||
2026-08-25 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $2.21 | -14,036 | 2,615,911 | -1% | -$30,969 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $16.56 | -9,845 | 343,259 | -3% | -$163,033 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $16.56 | -3,972 | 138,471 | -3% | -$65,776 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $16.56 | -2,798 | 164,048 | -2% | -$46,335 | ||||||
2026-08-27 | INDV | Indivior Pharmaceuticals, Inc. | Anderson Woodrow D | Chief Accounting Officer | P - Purchase | $35.69 | +1,500 | 27,638 | +6% | +$53,535 | ||||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| DM | 2026-08-24 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $83.10 | -9,096 | 54,324 | -14% | -$755,852 | |||||
2026-08-25 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $74.30 | -5,400 | 344,489 | -2% | -$401,220 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $10.77 | -3,035 | 264,378 | -1% | -$32,687 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $10.78 | -1,897 | 326,898 | -1% | -$20,450 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $10.78 | -3,296 | 318,326 | -1% | -$35,531 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $10.77 | -21,649 | 3,270,332 | -1% | -$233,160 | ||||||
2026-08-24 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.50 | -10 | 5,677,216 | 0% | -$45 | ||||||
| D | 2026-08-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.71 | -9,500 | 668,728 | -1% | -$4,918,273 | |||||
| M | 2026-08-24 | ANL | Adlai Nortye Group Ltd. | Ye Xiaofeng | CFO | S - Sale | $14.11 | -11,667 | 147,757 | -7% | -$164,635 | |||||
2026-08-25 | BMY | Bristol Myers Squibb Co | Holzer Phil M | SVP, Controller | S - Sale | $67.50 | -500 | 16,862 | -3% | -$33,750 | ||||||
2026-08-25 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $49.57 | -18,921 | 569,645 | -3% | -$937,957 | ||||||
| M | 2026-08-24 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $50.47 | -50,160 | 195,862 | -20% | -$2,531,582 | |||||
| M | 2026-08-24 | PRE | Prenetics Global Ltd | Rosin Brian J | CFO of IM8 (US) LLC | P - Purchase | $21.55 | +23,100 | 23,100 | New | +$497,700 | |||||
2026-08-24 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.33 | +1,794 | 601,911 | 0% | +$2,386 | ||||||
2026-08-21 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | GC | S - Sale | $16.97 | -20,975 | 600,787 | -3% | -$355,946 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Hohenleitner Susan | CFO | S - Sale | $3.86 | -1,558 | 227,520 | -1% | -$6,009 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $3.86 | -3,982 | 145,854 | -3% | -$15,358 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Bishop John E | See Remarks | S - Sale | $3.86 | -19,750 | 317,095 | -6% | -$76,174 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Brady James Parker | CHRO | S - Sale | $3.86 | -15,136 | 245,930 | -6% | -$58,378 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $3.86 | -8,562 | 409,410 | -2% | -$33,023 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | Chief Business Officer | S - Sale | $3.86 | -7,758 | 349,660 | -2% | -$29,922 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $3.86 | -10,739 | 367,456 | -3% | -$41,419 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $3.86 | -58,574 | 1,645,156 | -3% | -$225,914 | ||||||
| DM | 2026-08-21 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $18.96 | -10,906 | 0 | -100% | -$206,805 | |||||
2026-08-21 | PGEN | Precigen, Inc. | Agee Nancy H | Dir | P - Purchase | $7.23 | +3,411 | 309,187 | +1% | +$24,662 | ||||||
| DM | 2026-08-21 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale+OE | $7.50 | -50,000 | 468,865 | -10% | -$375,000 | |||||
| D | 2026-08-25 | PGEN | Precigen, Inc. | Tennant Phil | Chief Commercial Officer | S - Sale+OE | $7.50 | -79,166 | 141,992 | -36% | -$593,745 | |||||
| D | 2026-08-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $25.98 | -7,437 | 38,400 | -16% | -$193,189 | |||||
| D | 2026-08-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $511.97 | -9,500 | 668,728 | -1% | -$4,863,730 | |||||
| D | 2026-08-21 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $69.09 | -73,631 | 174,606 | -30% | -$5,087,225 | |||||
| D | 2026-08-24 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $26.91 | -125,000 | 122,802 | -50% | -$3,363,750 | |||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $15.54 | -9,589 | 63,899 | -13% | -$149,013 | ||||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $15.54 | -989 | 16,816 | -6% | -$15,369 | ||||||
| D | 2026-08-21 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale+OE | $37.62 | -9,445 | 13,071 | -42% | -$355,301 | |||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $15.54 | -1,457 | 16,220 | -8% | -$22,642 | ||||||
2026-08-21 | TEVA | Teva Pharmaceutical Industries Ltd | Satchi-Fainaro Ronit | Dir | S - Sale | $37.25 | -415 | 111,986 | 0% | -$15,459 | ||||||
| DM | 2026-08-20 | PRE | Prenetics Global Ltd | Yeung Danny Sheng Wu | CEO | P - Purchase | $20.34 | +24,681 | 112,416 | +28% | +$501,998 | |||||
2026-08-24 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +2,100 | 9,360,756 | 0% | +$116 | ||||||
| M | 2026-08-20 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.77 | +1,025,867 | 4,853,818 | +27% | +$1,814,147 | |||||
| D | 2026-08-21 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale+OE | $30.00 | -2,827 | 39,581 | -7% | -$84,810 | |||||
2026-08-24 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $12.39 | +100,000 | 1,214,650 | +9% | +$1,239,000 | ||||||
2026-08-21 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.89 | -4,345 | 169,269 | -3% | -$51,663 | ||||||
2026-08-24 | ABCL | Abcellera Biologics Inc. | Hayden Michael R | Dir | P - Purchase | $10.64 | +53,613 | 1,491,642 | +4% | +$570,442 | ||||||
| D | 2026-08-24 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | S - Sale+OE | $65.07 | -25,000 | 37,025 | -40% | -$1,626,750 | |||||
2026-08-20 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $47.05 | -60,677 | 59,086 | -51% | -$2,854,853 | ||||||
| D | 2026-08-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $518.39 | -9,500 | 668,728 | -1% | -$4,924,666 | |||||
| D | 2026-08-20 | ARQT | Arcutis Biotherapeutics, Inc. | Curran Terrie | Dir | S - Sale+OE | $26.04 | -1,072 | 23,526 | -4% | -$27,912 | |||||
2026-08-20 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.37 | +11,899 | 600,117 | +2% | +$16,302 | ||||||
2026-08-21 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.65 | +20,000 | 73,533 | +37% | +$13,000 | ||||||
2026-08-20 | TNXP | Tonix Pharmaceuticals Holding Corp. | Bagger Richard H | Dir | P - Purchase | $12.60 | +1,000 | 1,000 | New | +$12,600 | ||||||
| DM | 2026-08-19 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $36.88 | -335,174 | 18,630,739 | -2% | -$12,360,813 | |||||
2026-08-19 | AEON | Aeon Biopharma, Inc. | Lynch Timothy P | 10% | P - Purchase | $0.21 | +1,150,000 | 6,500,000 | +21% | +$243,455 | ||||||
| D | 2026-08-19 | MANE | Veradermics, Inc | Montanova Capital, LLC | Dir | S - Sale+OE | $107.25 | -750,000 | 612,033 | -55% | -$80,437,500 | |||||
| D | 2026-08-20 | OMER | Omeros Corp | Cable Thomas J. | Dir | S - Sale+OE | $18.45 | -15,000 | 35,067 | -30% | -$276,773 | |||||
| M | 2026-08-19 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $72.22 | -25,000 | 1,524,860 | -2% | -$1,805,411 | |||||
| M | 2026-08-19 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.59 | -191,865 | 5,677,226 | -3% | -$879,719 | |||||
| D | 2026-08-19 | NUVB | Nuvation Bio Inc. | Hattersley Gary | Chief Scientific Officer | S - Sale+OE | $7.09 | -100,000 | 0 | -100% | -$709,240 | |||||
| D | 2026-08-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $521.02 | -9,500 | 668,728 | -1% | -$4,949,717 | |||||
| D | 2026-08-20 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $523.14 | -8,300 | 45,172 | -16% | -$4,342,079 | |||||
2026-08-19 | TAK | Takeda Pharmaceutical Co Ltd | Plump Andrew Stewart | Pres, R, D | S - Sale | $18.49 | -19,651 | 1,028,225 | -2% | -$363,347 | ||||||
2026-08-19 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $12.63 | -31,487 | 195,444 | -14% | -$397,681 | ||||||
| DM | 2026-08-19 | LQDA | Liquidia Corp | Rielly-Gauvin Katherine | Dir | S - Sale+OE | $74.07 | -55,182 | 44,637 | -55% | -$4,087,435 | |||||
2026-08-19 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.00 | -28,468 | 141,053 | -17% | -$398,552 | ||||||
2026-08-20 | ELAN | Elanco Animal Health Inc | Kurzius Lawrence Erik | Dir | P - Purchase | $23.40 | +40,000 | 188,647 | +27% | +$935,920 | ||||||
2026-08-19 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $27.00 | -260 | 35,635 | -1% | -$7,020 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |